Xtant Medical completes secondary private sale of 73.1 million shares.

Xtant Medical Holdings, a global medical technology company, has completed a secondary private sale of 73.1 million shares of common stock held by OrbiMed Advisors to existing and new stockholders, led by Nantahala Capital Management. The sale terminates the investor rights agreement between Xtant and OrbiMed, providing Xtant greater strategic and operational flexibility. The proceeds from the sale will support the company's shift to higher-margin orthobiologics and new product launches.